home / stock / lyra / lyra quote
Last: | $4.72 |
---|---|
Change Percent: | 0.19% |
Open: | $5.16 |
Close: | $4.72 |
High: | $5.2 |
Low: | $4.7001 |
Volume: | 157,109 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.72 | $5.16 | $4.72 | $5.2 | $4.7001 | 157,109 | 04-26-2024 |
$5.17 | $5.2 | $5.17 | $5.28 | $5.13 | 105,303 | 04-25-2024 |
$5.23 | $5.25 | $5.23 | $5.42 | $5.16 | 120,741 | 04-24-2024 |
$5.21 | $5.24 | $5.21 | $5.39 | $5.21 | 228,918 | 04-23-2024 |
$5.21 | $5.2 | $5.21 | $5.28 | $5.07 | 240,842 | 04-22-2024 |
$5.19 | $5.32 | $5.19 | $5.48 | $5.12 | 233,963 | 04-19-2024 |
$5.39 | $5.45 | $5.39 | $5.52 | $5.21 | 387,833 | 04-18-2024 |
$5.405 | $5.4 | $5.405 | $5.77 | $5.27 | 299,203 | 04-17-2024 |
$5.4 | $5.24 | $5.4 | $5.48 | $5.19 | 244,109 | 04-16-2024 |
$5.27 | $5.3 | $5.27 | $5.39 | $5.2 | 240,217 | 04-15-2024 |
$5.28 | $5.34 | $5.28 | $5.55 | $5.16 | 264,004 | 04-12-2024 |
$5.44 | $5.31 | $5.44 | $5.5 | $5.25 | 269,368 | 04-11-2024 |
$5.25 | $5.1 | $5.25 | $5.29 | $4.94 | 237,539 | 04-10-2024 |
$5.24 | $5.25 | $5.24 | $5.3399 | $4.99 | 377,987 | 04-09-2024 |
$5.1 | $5.02 | $5.1 | $5.2 | $5.0101 | 175,020 | 04-08-2024 |
$5.02 | $5.34 | $5.02 | $5.41 | $5.01 | 423,632 | 04-05-2024 |
$5.28 | $5.46 | $5.28 | $5.66 | $5.28 | 299,354 | 04-04-2024 |
$5.46 | $5.71 | $5.46 | $5.83 | $5.45 | 264,415 | 04-03-2024 |
$5.61 | $6.17 | $5.61 | $6.29 | $5.59 | 217,153 | 04-02-2024 |
$6.25 | $6.31 | $6.25 | $6.355 | $5.65 | 1,330,031 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Lyra Therapeutics Inc. Company Name:
LYRA Stock Symbol:
NASDAQ Market:
WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company developing inn...
WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnol...
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chi...